Mefatinib as first-line treatment of patients with advanced non-small cell lung cancer harboring rare EGFR mutations.

科研成果详情

题名	Mefatinib as first-line treatment of patients with advanced non-small cell lung cancer harboring rare EGFR mutations.
作者	Wang, Pingli ; Cao, Liming ; Tian, Panwen ; Ren, Shengxiang ; Miao, Liyun ; Zhou, Chengzhi ; Fan, Yun ; Li, Yuping ; Lv, Dongqing ; Zhao, Xin ; Yang, Mei ; Zhu, Chaonan ; Xu, June ; Song, Yong ; Wang, Kai
发表日期	2022-06-01
会议录名称	JOURNAL OF CLINICAL ONCOLOGY 影响因子和分区
语种	英语
原始文献类型	Meeting Abstract
资助项目	HangZhou ZhongMei HuaDong Pharmaceutical Company
出版者	LIPPINCOTT WILLIAMS & WILKINS
出版地	PHILADELPHIA
ISSN	0732-183X
EISSN	1527-7755
卷号	40
期号	16
页数	1
WOS类目	Oncology
WOS研究方向	Oncology
WOS记录号	WOS:000863680302288
收录类别	SCIE ; CPCI
自定义期刊分类	T2(A)类
TOP期刊	TOP期刊
会议名称	Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
会议地点	ELECTR NETWORK
会议日期	JUN 03-07, 2022
引用统计	被引频次[WOS]：0 [WOS记录] [WOS相关记录]
文献类型	会议论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/167281
专题	第一临床医学院（信息与工程学院）、附属第一医院_内科学_呼吸与危重症医学科
作者单位	1.Zhejiang Univ, Dept ment Resp Med, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China; 2.Cent South Univ, Dept Resp Med, Xiangya Hosp, Changsha, Peoples R China; 3.Sichuan Univ, Dept Resp & Crit Care Med, West China Hosp, Chengdu, Peoples R China; 4.Shanghai Pulm Hosp, Dept Oncol, Shanghai, Peoples R China; 5.Nanjing Univ, Dept Resp Med, Affiliated Drum Tower Hosp, Med Sch, Nanjing, Peoples R China; 6.Zhejiang Canc Hosp, Dept Thorac Oncol, Guangzhou, Peoples R China; 7.Wenzhou Med Univ, Dept Pulm & Crit Care Medi cine, Affiliated Hosp 1, Wenzhou, Peoples R China; 8.Wenzhou Med Univ, Dept Resp Med, Taizhou Hosp, Linhai, Peoples R China; 9.Nanjing Med Univ, Jiangsu Prov Hosp, Dept Resp & Crit Care Med, Affiliated Hosp 1, Nanjing, Peoples R China; 10.HangZhou ZhongMei HuaDong Pharmaceut Co, Huadong Global Dev Ctr, Hangzhou, Peoples R China; 11.Gen Hosp Eastern Theater Command, Dept Resp Med, Nanjing, Peoples R China; 12.Zhejiang Univ, Dept Resp Med, Affiliated Hosp 2, Sch Med, Hangzhou, Yiwu, Peoples R China; 13.Zhejiang Univ, Dept Resp & Criti cal Care Med, Affiliated Hosp 4, Sch Med, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Wang, Pingli,Cao, Liming,Tian, Panwen,et al. Mefatinib as first-line treatment of patients with advanced non-small cell lung cancer harboring rare EGFR mutations.[C]. PHILADELPHIA:LIPPINCOTT WILLIAMS & WILKINS,2022.